ENHANCEMENT OF HUMORAL RESPONSE AGAINST HUMAN INFLUENZA VACCINE WITH THE SIMPLE SUBMICRON OIL/WATER EMULSION ADJUVANT MP59

被引:107
作者
OTT, G
BARCHFELD, GL
VANNEST, G
机构
[1] Chiron Corporation, Emeryville, CA 94608
[2] Emeryville, CA 94608
关键词
VACCINE; ADJUVANT; INFLUENZA;
D O I
10.1016/0264-410X(95)00089-J
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human influenza subunit vaccines are not fully protective in either the very young or elderly populations where risk is greatest. The toe of an adjuvant to enhance antibody titer is an attractive option to increase vaccine efficacy. A series of squalene/H2O emulsions stabilized either by the amphipathic muramyl peptide MTP-PE (sodium N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanyl-2-(1',2'-dipalmitoyl-sn-glycero-3'phospho)ethylamide) or by mixtures of the sorbitan oleate surfactants Tween 80 and Span 85 have been tested as adjuvants with influenza vaccine, Combination of influenza vaccine with the Tween/Span stabilized emulsions has resulted in significantly higher antibody titers to vaccine in an extensive series of naive animal models, The use of submicron emulsion droplets is significant in determination of adjuvant activity, while the presence of the muramyl peptide is not required for adjuvant activity, The 200-300 nm diameter emulsion formulation MF59 containing only the low toxicity components squalene, Tween 80 and Span 85 has been shown to enhance titers from 5 to 250 times that achievable, vith vaccine alone.
引用
收藏
页码:1557 / 1562
页数:6
相关论文
共 30 条
[1]  
Allison A C, 1990, Semin Immunol, V2, P369
[2]   SAFETY AND IMMUNOGENICITY OF A 45-MU-G SUPPLEMENTAL DOSE OF INACTIVATED SPLIT-VIRUS INFLUENZA-B VACCINE IN THE ELDERLY [J].
ARDEN, NH ;
PATRIARCA, PA ;
LUI, KJ ;
HARMON, MW ;
BRANDON, F ;
KENDAL, AP .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (04) :805-806
[3]   DISSOCIATION OF IMMUNOSTIMULANT ACTIVITIES OF MURAMYL DIPEPTIDE (MDP) BY LINKING AMINO-ACIDS OR PEPTIDES TO THE GLUTAMINYL RESIDUE [J].
AUDIBERT, F ;
PARANT, M ;
DAMAIS, C ;
LEFRANCIER, P ;
DERRIEN, M ;
CHOAY, J ;
CHEDID, L .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 96 (02) :915-923
[4]   COMPARATIVE TRIAL OF INFLUENZA VACCINES .2. ADVERSE REACTIONS IN CHILDREN AND ADULTS [J].
BARRY, DW ;
MAYNER, RE ;
HOCHSTEIN, HD ;
DUNLAP, RC ;
RASTOGI, SC ;
HANNAH, JE ;
BLACKBURN, RJ ;
SULLIVAN, JL ;
GERETY, RJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1976, 104 (01) :47-59
[5]  
BECKENDORF J, 1995, TOXICOLOGIST, V15, P69
[6]   FACTORS AFFECTING EMULSION STABILITY, AND HLB CONCEPT [J].
BOYD, J ;
SHERMAN, P ;
PARKINSONL, C .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1972, 41 (02) :359-+
[7]   ENHANCEMENT OF ANTIBODY-RESPONSES TO INFLUENZA-B VIRUS HEMAGGLUTININ BY USE OF A NEW ADJUVANT FORMULATION [J].
BYARS, NE ;
ALLISON, AC ;
HARMON, MW ;
KENDAL, AP .
VACCINE, 1990, 8 (01) :49-56
[8]   ENHANCEMENT OF THE PROTECTIVE EFFECT OF INACTIVATED INFLUENZA-VIRUS VACCINE BY CYTOKINES [J].
CAO, M ;
SASAKI, O ;
YAMADA, A ;
IMANISHI, J .
VACCINE, 1992, 10 (04) :238-242
[9]  
CATE TR, 1983, REV INFECT DIS, V5, P737
[10]  
Chernoff D, 1995, VACCINE DESIGN SUBUN, P277